3191 results for «988»

Filter By

3191 results

Mastering simple and complex LAA closure: a step-by-step case-based approach

16 Nov 2025 – From PCR London Valves 2025

This case-based session offers a comprehensive approach to mastering left atrial appendage (LAA) closure, emphasizing the critical role of imaging from pre-procedural planning through execution. It covers patient selection, procedural strategies from experienced operators, device selection tailored to anatomy, and nuanced decision-making during challenging device releases...

Mastering simple and complex LAA closure: a step-by-step case-based approach

LAA closure is evolving: are you ready?

17 Nov 2025 – From PCR London Valves 2025

This session addresses the evolving landscape of left atrial appendage (LAA) closure in stroke prevention for atrial fibrillation patients. It reviews unmet clinical needs, evaluates the latest evidence and guideline recommendations, and identifies patient populations that benefit most from LAA closure, with discussions on balancing efficacy...

LAA closure is evolving: are you ready?

Advancing structural heart with 3D ICE and device guidance

17 Nov 2025 – From PCR London Valves 2025

This PCR London Valves 2025 session explores how 3D TEE, 3D intracardiac echocardiography (ICE), and DeviceGuide technology sharpen procedural accuracy, strengthen operator confidence, and streamline decision-making in real time.

You’ll see how clearly defined team roles enhance both safety and efficiency, and how thoughtful workflow integration can reduce...

Advancing structural heart with 3D ICE and device guidance

Mastering complex TAVI: overcoming key clinical challenges and achieving optimal outcomes with the Evolut FX+

17 Nov 2025 – From PCR London Valves 2025

This session offers an in-depth review of complex TAVI cases, focusing on overcoming clinical challenges and achieving optimal outcomes with the Evolut FX+ device. Participants will learn about recent advances in TAVI indications for younger and asymptomatic patients, strategies for managing TAV in surgical aortic valve...

Mastering complex TAVI: overcoming key clinical challenges and achieving optimal outcomes with the Evolut FX+

A new era for aortic regurgitation: how new guidelines and dedicated devices for AR will redefine treatment

18 Nov 2025 – From PCR London Valves 2025

This session examines the evolving treatment landscape for aortic regurgitation (AR) in light of new ESC guidelines and dedicated devices such as the JenaValve Trilogy System. It provides an in-depth look at refined diagnosis, optimized treatment strategies, and presents real-world data and clinical cases that highlight...

A new era for aortic regurgitation: how new guidelines and dedicated devices for AR will redefine treatment

Beyond TAVI

16 Nov 2025 – From PCR London Valves 2025

This session offers a glimpse into cutting-edge structural heart interventions beyond TAVI. It introduces novel devices in early development stages targeting aortic valve stenosis and leaflet modification, discusses strategies to facilitate or defer TAVI, and provides opportunities for engagement with early-stage start-up partners innovating in structural...

Outcomes in patients with atrial fibrillation randomized to receive LAA closure or oral anticoagulation: Primary results of the CHAMPION-AF clinical trial

28 Mar 2026

During the first Late-Breaking Trial session of the 2026 ACC Congress held in New Orleans, Saibal Kar, principal investigator of the CHAMPION-AF trial, presented the 3-year results of this groundbreaking study, which were simultaneously published in the NEJM (DOI: 10.1056/NEJMoa2517213).

Luigi Biasco

Author

Luigi Biasco
CHAMPION-AF: LAAC vs oral anticoagulation in atrial fibrillation

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

05 Sep 2023

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Alessandro Sticchi

Author

Alessandro Sticchi
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

The JenaValve Trilogy™ heart valve system in high surgical risk patients with symptomatic, severe aortic regurgitation: The ALIGN AR Trial

25 Oct 2023

Nicola Ryan provides her take on the ALIGN AR trial which was presented by Vinod H. Thourani at TCT Congress 2023. The Align AR trial is a prospective single-arm investigation device exemption study assessing the safety and efficacy of the Trilogy transcatheter heart valve system in patients with...

Nicola Ryan

Author

Nicola Ryan
Initial Outcomes of the JenaValve Trilogy Transcatheter Aortic Valve Replacement System in High-Risk Patients with Symptomatic Severe Native Aortic Regurgitation (ALIGN-AR)

TRILUMINATE pivotal: A landmark randomized clinical trial of transcatheter tricuspid valve edge-to-edge repair for tricuspid regurgitation

04 Mar 2023

Jonathan Curio and Alex Sticchi provide their take on this clinical trial which was presented by Paul Sorajja at the American College of Cardiology Scientific Session (ACC.23/WCC).

Alessandro Sticchi

Author

Alessandro Sticchi
Jonathan Curio

Author

Jonathan Curio
Live from ACC.23/WCC: TRILUMINATE pivotal

TRI.fr trial - Multicentric randomised evaluation of the transcatheter edge-to-edge repair in the treatment of severe isolated secondary tricuspid regurgitation

31 Aug 2024

Alex Sticchi provides his take on the results of the TRI.FR trial presented by Erwan Donal at the ESC Congress 2024 in London.

Alessandro Sticchi

Author

Alessandro Sticchi
Tri.fr trial
Didn’t find what you were looking for?